{Reference Type}: English Abstract
{Title}: [Novel germline SAMD9 mutation in an elderly patient with myelodysplastic syndrome].
{Author}: Uchida T;Fujii T;Ohara S;Imai Y;Inoue M;Harada Y;Harada H;Hagihara M;Uchida T;Fujii T;Ohara S;Imai Y;Inoue M;Harada Y;Harada H;Hagihara M;
{Journal}: Rinsho Ketsueki
{Volume}: 63
{Issue}: 8
{Year}: 2022
暂无{DOI}: 10.11406/rinketsu.63.865
{Abstract}: An 80-year-old Japanese male patient presented to our hospital with complaints of fatigue. His peripheral blood tests revealed pancytopenia with predominant lymphocytes and without blasts. The bone marrow (BM) aspiration was unsuccessful due to a dry tap, and the subsequent BM biopsy revealed hypocellular marrow with fibrosis. He was diagnosed with myelodysplastic syndrome (MDS) with excess blasts (EB)-2 based on CD34-positive cells. The chromosome analysis of the BM revealed monosomy 7, and the SAMD9 W22* mutation was detected (variant allele frequency [VAF] of 51.22%) using next-generation sequencing. An identical mutation was observed in the buccal mucosa (VAF of 50%), which was confirmed as a germline mutation. The SAMD9 gene mutation is reported as one of the causative genes for MIRAGE syndrome and child-onset MDS. The present case was considered a loss-of-function mutation due to the near full-length SAMD9 deletion. This is the first adult case of MDS with SAMD9 W22* as a germline mutation.